Pernix Therapeutics Holdings (PTX) Posts Q2 GAAP Loss of 16c/Share

Pernix Therapeutics Holdings (NASDAQ: PTX) reported Q2 EPS of ($0.16), $0.11 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $17.4 million versus the consensus estimate of $26.2 million.

For earnings history and earnings-related data on Pernix Therapeutics Holdings (PTX) click here.

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Pulmatrix (PULM) Reports Q2 Loss of $0.29
• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance